• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Key Managed Care Considerations for IgA Nephropathy Treatment

Opinion
Video

Panelists discuss how immunoglobulin A (IgA) nephropathy’s progressive nature and significant economic impact demand a shift in payer perspective toward investing in disease-modifying therapies that, despite higher upfront costs, can prevent the extraordinary expenses of dialysis and transplantation while preserving patients’ quality of life and productivity.

Key Considerations for Payers: IgA Nephropathy and Emerging Therapies

Disease Impact Context

  • Progressive nature: IgA nephropathy is not benign—30%-40% of patients progress to end-stage kidney disease(ESKD) within 20-30 years despite current standard therapies
  • Young patient population: Disease typically affects individuals in their 20s-40s, creating decades of health care utilization and productivity impact
  • Limited current options: Standard therapies (renin-angiotensin-aldosterone system blockade, steroids) provide insufficient disease control for many patients
  • High-cost trajectory: The lifetime cost of an IgAN patient progressing to ESKD exceeds $1 million-$2 million when considering dialysis, transplantation, and indirect costs

Value Proposition of Targeted Therapies

  • Disease modification potential: Novel therapies target specific pathogenic mechanisms rather than merely managing symptoms
  • Preservation of kidney function: Even modest delays in progression (3-5 years) generate substantial cost savings by delaying ESKD
  • Reduced downstream resource utilization: Fewer hospitalizations, emergency visits, and complication management
  • Workforce preservation: Maintained productivity and delayed disability have significant societal economic benefit

Access Considerations

  • Appropriate patient selection: Risk stratification tools can identify patients most likely to benefit from advanced therapies
  • Complementary to standard care: Novel agents should augment, not replace, optimized supportive care
  • Response monitoring protocols: Clear parameters for assessing treatment efficacy (proteinuria reduction, estimated glomerular filtration rate stabilization)
  • Step-therapy approach: Rational sequencing can optimize cost-effectiveness while ensuring appropriate access

Evidence Development

  • Surrogate end point context: Proteinuria reduction is the best available short-term marker of treatment efficacy
  • Clinical trial limitations: Standard ESKD end points require decades of follow-up, making trial design challenging
  • Real-world evidence importance: Need for collaborative registry data to assess long-term outcomes
  • Patient-reported outcomes: Critical to capture quality of life and functional status improvements not reflected in laboratory values

Partnership Opportunities

  • Risk-sharing arrangements: Consider outcomes-based agreements tied to measurable clinical parameters
  • Value-based pathway development: Collaborative creation of evidence-based coverage criteria
  • Early intervention incentives: Alignment of coverage policies to encourage timely diagnosis and treatment
  • Total cost of care perspective: Evaluation of therapies within comprehensive kidney care models rather than in isolation

Early access to effective targeted therapies represents an investment in preventing high-cost ESKD care while preserving patient quality of life and productivity.

Related Videos
Dr Sheela Rao
4 experts are featured in this series.
4 experts are featured in this series.
5 experts in this video
5 experts in this video
5 experts are featured in this series
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.